Product Overview
Triclabendazole, HRP conjugate
Storage
2-8°C short term, -20°C long term
Introduction
Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. Fascioliasis is a parasitic infection often caused by the helminth,?Fasciola hepatica, which is also known as “the common liver fluke” or “the sheep liver fluke” or by?Fasciola gigantica, another helminth. These parasites can infect humans following ingestion of larvae in contaminated?water?or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.
Antigen Description
Triclabendazole, the active ingredient, is a benzimidazole. It binds to tubulin impairing intracellular transport mechanisms and interferes with protein synthesis. Triclabendazole is specifically active against Fasciola, Fascioloides and Paragonimus. The unique efficacy of FASINEX against the early immature and immature Fasciola stages makes this product particularly useful for the treatment of outbreaks of acute and subacute fasciolosis and for the strategic control of Fasciola infections. In addition, the efficacy against the 3 stages accelerates recovery of health and thus productivity. FASINEX is indicated for the treatment and control of acute, subacute and chronic fasciolosis due to early immature, immature and adult stages of Fasciola hepatica and Fasciola gigantica in cattle, sheep and goats.
Citations
Publication ()
Have you cited DAG1326 in a publication?
Let us know and earn a reward for your research.
COA
Loading ......
